ArticleOncotarget2015
IDO-GCN2 and autophagy in inflammation.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- GCN2 in Cancer: Molecular Mechanisms to Therapeutic Potential.Current cancer drug targets · 2026Review
- Autophagy in Cancer Immunotherapy.Cells · 2022Review
- Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy.Signal transduction and targeted therapy · 2022Review
- Kynurenines as a Novel Target for the Treatment of Malignancies.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The IFN-γ-IDO1-kynureine pathway-induced autophagy in cervical cancer cell promotes phagocytosis of macrophage.International journal of biological sciences · 2021Article
- Trial watch: IDO inhibitors in cancer therapy.Oncoimmunology · 2020Review
- Aminoacyl-tRNA synthetase inhibition activates a pathway that branches from the canonical amino acid response in mammalian cells.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Metabolic Targets for Treatment of Autoimmune Diseases.Immunometabolism · 2020Article
- The relationship between autophagy and the immune system and its applications for tumor immunotherapy.Molecular cancer · 2019Review
- Reply to 'F508del-CFTR is not corrected by thymosin α1'.Nature medicine · 2018Article
- Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice.Frontiers in immunology · 2018Article
- Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis.Nature medicine · 2017Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.